[ad_1]
When the bigger public imagines bioprinting they have a tendency to think about a machine that builds mobile tissues including one cell after the opposite. Usually, that’s not the case, as most applied sciences leverage bioinks and hydrogels to create scaffolds and deposit the mobile supplies. Fluicell’s microfluidic bioprinting know-how first delivered single-cell printing capabilities with the unique Biopixlar platform in 2019. Now, with the brand new Biopixlar AER, these capabilities turn into accessible to a wider goal of customers. We solely caught up with Victoire Viannay, CEO of Fluicell, to be taught extra about this know-how and the chances it opens for brand new functions.
Fluicell was based ten years in the past, as a spin-off firm from Chalmers College of Expertise in Gothenburg, Sweden, with the ambition to offer single-cell applied sciences to push the boundaries of science. For the reason that begin, the corporate has grown from a one-product firm specializing in single-cell biology to a five-platform firm offering analysis devices, equipment, providers and analysis and growth collaborations throughout single-cell biology, bioprinting and regenerative medication. It has a presence in a lot of the world, with most of methods at the moment used within the USA and all through Europe, in well-known Universities, analysis institutes and pharmaceutical firms.
“Immediately, we’re a crew of 19 progressive and forward-thinking folks,” the Fluicell CEO instructed 3dpbm. “We’re a small crew, however we intention to develop the corporate additional as we set up increasingly more of our merchandise in labs all over the world and as we progress in our regenerative medication program by way of partnerships.”
Fluicell is a supplier of analysis options in single-cell biology, bioprinting and regenerative medication. “Because of this we’re not solely promoting you an instrument,” Victoire Viannay clarifies, “we additionally present equipment and consumables to cowl the bioprinting course of from begin to end. Our dedication to offering a whole analysis resolution package deal additionally extends to contract analysis and growth work the place we assist clients to develop new functions or carry out pilot research utilizing our distinctive know-how.”
On prime of this, Fluicell engages in collaborative analysis partnerships frequently. One current instance of that is the continuing EU-funded analysis mission BIRDIE, which goals at creating in vitro renal fashions utilizing bioprinting and organ-on-chip applied sciences, coordinated by Maastricht College, with companions in France and Germany.
The cell-by-cell benefit
“Fluicell is a microfluidics firm at coronary heart – Victoire Viannay instructed us – with a selected focus in direction of creating instruments to regulate liquid flows in open volumes. The know-how lets us, as an example, expose particular person cells to drug compounds with out taking them out of their native surroundings, or, within the case of our Biopixlar bioprinting know-how, deposit cells with precision on the degree of single cells immediately in tradition media to create detailed organic tissues.”
The important thing benefit of the Biopixlar platform is that open quantity microfluidic know-how lets customers create tissues with very excessive precision and backbone that higher characterize cell configurations in actual tissues. This is applicable to single-cell arrays or in vitro analysis fashions of tissue-based therapeutics. As well as, since Biopixlar doesn’t require any bioink, customers can place the cells shut collectively in a method that promotes intercellular communication, which is necessary for correct tissue maturation and performance. As well as, little or no beginning materials is required to generate tissues, making the know-how properly suited to, amongst different issues, precision medication functions utilizing patient-derived materials.
On prime of the numerous benefits talked about above, a vital distinction between Biopixlar and extrusion-based methods is that the printed cells expertise little or no mechanical stress in the course of the printing course of, leading to higher cell survivability. “The distinction,” Victoire Viannay defined, “is that Biopixlar prints immediately in tradition media utilizing laminar flows, which creates a really cell-friendly surroundings, contemplating that the bioink themselves may cause cell-damaging shear stresses.
“With extrusion bioprinting, there may be additionally little or no management of how the cells are positioned contained in the bioink and within the printed tissue, which can have an effect on tissue perform. Biopixlar avoids this by printing the cells immediately, thereby selling elevated organic performance. With respect to laser-assisted bioprinting, the Biopixlar platform does away with complicated instrumentation and the necessity of a photosensitive matrix to sample cells.”
The Biopixlar AER compact manufacturing cell
The brand new Biopixlar AER was launched to supply single-cell bioprinting in a compact format. It’s high-end bioprinting that matches in a normal laminar movement hood or biosafety cupboard and that’s straightforward to combine into any laboratory workflow. It’s straightforward to arrange and begin utilizing, and simple to function utilizing the gamepad controller.
“Biopixlar AER’s purpose is to carry the chances supplied by the Biopixlar know-how into laboratories that favor a excessive diploma of course of parallelization and automation,” Victoire Viannay identified “It has been designed for laboratory workflow integration and simple person onboarding, making the platform an excellent match for big analysis laboratories with many non-specialized customers. These can embody pharmaceutical analysis laboratories, core amenities and different massive analysis infrastructures. The perfect buyer is one who desires to get extra and higher information from their in vitro analysis fashions, whether or not it’s to raised perceive the organic mechanisms behind a particular illness or to acquire extra dependable insights into the consequences of a selected drug candidate.”
Proceed studying our unique interview with Victoire Viannay, CEO of Fluicell, and be taught every thing you must know concerning the bioink-free Biopixlar AER bioprinter in 3dpbm’s latest AM Focus 2022 Bioprinting eBook (web page 31). Our AM Focus eBooks are 100% free to view on-line or obtain (no registration required).
[ad_2]
